OBJECTIVE: This study addresses the following 3 questions posed by the US Preventive Services Task Force: (1) at what age should screening for cervical cancer begin; (2) at what age should screening for cervical cancer end; and (3) how do the benefits and potential harms of screening strategies that use human papillomavirus DNA testing in conjunction with cytology (cotesting) compare with those strategies that use cytology only? MATERIALS AND METHODS: A Markov model was updated and used to quantify clinical outcomes (i.e., colposcopies, cancers, and life expectancy) associated with different screening strategies. RESULTS: Screening in the teenaged years is associated with a high number of colposcopies (harms), small differences in cancers detected and, as a result, small gains in life expectancy (benefits). Screening women beginning in the early 20s provides a reasonable balance of the harms and benefits of screening. Among women who have been screened according to the current recommendations for cervical cancer (beginning at age 21 years and conducted every 3 years with cytology), screening beyond 65 years is associated with small additional gains in life expectancy but large increases in colposcopies. For cotesting, a strategy of cytology only conducted every 3 years, followed by cotesting conducted every 5 years (for women ≥30 years), is associated with fewer colposcopies and greater gains in life expectancy compared with screening with cytology only conducted every 3 years. CONCLUSIONS: The results of this modeling study support current US Preventive Services Task Force recommendations for cervical cancer screening.
OBJECTIVE: This study addresses the following 3 questions posed by the US Preventive Services Task Force: (1) at what age should screening for cervical cancer begin; (2) at what age should screening for cervical cancer end; and (3) how do the benefits and potential harms of screening strategies that use human papillomavirus DNA testing in conjunction with cytology (cotesting) compare with those strategies that use cytology only? MATERIALS AND METHODS: A Markov model was updated and used to quantify clinical outcomes (i.e., colposcopies, cancers, and life expectancy) associated with different screening strategies. RESULTS: Screening in the teenaged years is associated with a high number of colposcopies (harms), small differences in cancers detected and, as a result, small gains in life expectancy (benefits). Screening women beginning in the early 20s provides a reasonable balance of the harms and benefits of screening. Among women who have been screened according to the current recommendations for cervical cancer (beginning at age 21 years and conducted every 3 years with cytology), screening beyond 65 years is associated with small additional gains in life expectancy but large increases in colposcopies. For cotesting, a strategy of cytology only conducted every 3 years, followed by cotesting conducted every 5 years (for women ≥30 years), is associated with fewer colposcopies and greater gains in life expectancy compared with screening with cytology only conducted every 3 years. CONCLUSIONS: The results of this modeling study support current US Preventive Services Task Force recommendations for cervical cancer screening.
Authors: George Koliopoulos; Marc Arbyn; Pierre Martin-Hirsch; Maria Kyrgiou; Walter Prendiville; Evangelos Paraskevaidis Journal: Gynecol Oncol Date: 2006-11-03 Impact factor: 5.482
Authors: Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco Journal: N Engl J Med Date: 2007-10-18 Impact factor: 91.245
Authors: Ann G Zauber; Iris Lansdorp-Vogelaar; Amy B Knudsen; Janneke Wilschut; Marjolein van Ballegooijen; Karen M Kuntz Journal: Ann Intern Med Date: 2008-10-06 Impact factor: 25.391
Authors: Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon Journal: Am J Obstet Gynecol Date: 2007-10 Impact factor: 8.661
Authors: Amy B Knudsen; Ann G Zauber; Carolyn M Rutter; Steffie K Naber; V Paul Doria-Rose; Chester Pabiniak; Colden Johanson; Sara E Fischer; Iris Lansdorp-Vogelaar; Karen M Kuntz Journal: JAMA Date: 2016-06-21 Impact factor: 56.272
Authors: Lisa M Pollack; Donatus U Ekwueme; Mei-Chuan Hung; Jacqueline W Miller; Su-Hsin Chang Journal: Cancer Causes Control Date: 2020-05-20 Impact factor: 2.506
Authors: Jane J Kim; Anna Na Tosteson; Ann G Zauber; Brian L Sprague; Natasha K Stout; Oguzhan Alagoz; Amy Trentham-Dietz; Katrina Armstrong; Sandi L Pruitt; Carolyn M Rutter Journal: J Natl Cancer Inst Date: 2015-11-03 Impact factor: 13.506
Authors: Kavishwar B Wagholikar; Kathy L MacLaughlin; Christopher G Chute; Robert A Greenes; Hongfang Liu; Rajeev Chaudhry Journal: AMIA Jt Summits Transl Sci Proc Date: 2015-03-25
Authors: Juan C Felix; Michael J Lacey; Jeffrey D Miller; Gregory M Lenhart; Mark Spitzer; Rucha Kulkarni Journal: J Womens Health (Larchmt) Date: 2016-03-29 Impact factor: 2.681